Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


'Right-To-Try' Has US FDA Support: Scaled-Back House Bill Retains Agency Oversight

Executive Summary

Commissioner Gottlieb’s recent remarks on pending federal 'Right-to-Try' legislation were his most positive to date; he pushed back on earlier versions that would have removed FDA from process. 

Related Content

Expanded Access Programs Eyed For Data-Gathering Purposes
Right-To-Try Opponents Brace For Last Chance To Stop Bill
Right-To-Try Legislation Must Change Language To Narrow Spectrum Of Patients, Gottlieb Says
Implementing User Fees Should Be Lighter Lift For FDA This Time Around; Bill Heads To White House
'Right To Try' And PDUFA VI: Patient Advocates, Industry Fight Senate Add-On





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts